Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

eculizumab 3ublituximab 1ravulizumab 1Sugars 1Rituximab 1Plasma Exchange 1OM 89 1N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide 1Mitoxantrone 1LFB-R603 1Interferon beta-1a 1Immunoglobulins, Intravenous 1Adrenal Cortex Hormones 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Myelitis, Transverse × Rituximab × Clear all
NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

University of California, San Francisco

Phase 1 Completed
20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡